{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T10:01:58Z","timestamp":1770285718004,"version":"3.49.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.det.2024.02.003","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T03:55:54Z","timestamp":1711511754000},"page":"377-386","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Evolving Landscape of Biologic Therapy for Pediatric Psoriasis"],"prefix":"10.1016","volume":"42","author":[{"given":"Huongly","family":"Do","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayla","family":"Babbush Graber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen A.","family":"Chernoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura E.","family":"Melnick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.det.2024.02.003_bib1","first-page":"187","article-title":"Prevalence of Psoriasis in Children and Adolescents in the United States: A Claims-Based Analysis","volume":"17","author":"Paller","year":"2018","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.02.003_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000251595","article-title":"The natural history of psoriasis in 5,600 patients","volume":"148","author":"Farber","year":"1974","journal-title":"Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.02.003_bib3","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1046\/j.1525-1470.2000.01746.x","article-title":"A\u00a0comparative study of pediatric onset psoriasis with adult onset psoriasis","volume":"17","author":"Raychaudhuri","year":"2000","journal-title":"Pediatr Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.02.003_bib4","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jaad.2019.08.049","article-title":"Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients","volume":"82","author":"Menter","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.02.003_bib5","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jaad.2009.07.029","article-title":"Incidence of psoriasis in children: A population-based study","volume":"62","author":"Tollefson","year":"2010","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.02.003_bib6","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/jid.2009.59","article-title":"The IL-23\/Th17 axis in the immunopathogenesis of psoriasis","volume":"129","author":"Di Cesare","year":"2009","journal-title":"J\u00a0Invest Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.02.003_bib7","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.jaci.2011.01.054","article-title":"Contrasting pathogenesis of atopic dermatitis and psoriasis\u2014Part II: Immune cell subsets and therapeutic concepts","volume":"127","author":"Guttman-Yassky","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"Suppl 1","key":"10.1016\/j.det.2024.02.003_bib8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/ijd.13372","article-title":"Infections and skin diseases mimicking diaper dermatitis","volume":"55","author":"Van Gysel","year":"2016","journal-title":"Int J Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.02.003_bib9","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/pde.13382","article-title":"Pediatric psoriasis: Evolving perspectives","volume":"35","author":"Eichenfield","year":"2018","journal-title":"Pediatr Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.02.003_bib10","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1080\/09546634.2022.2059051","article-title":"Managing pediatric psoriasis: update on treatments and challenges\u2014a review","volume":"33","author":"Hebert","year":"2022","journal-title":"J\u00a0Dermatol Treat"},{"issue":"2","key":"10.1016\/j.det.2024.02.003_bib11","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/1093526617748781","article-title":"Histopathology of Cutaneous Inflammatory Disorders in Children","volume":"21","author":"Hsi","year":"2018","journal-title":"Pediatr Dev Pathol"},{"issue":"1","key":"10.1016\/j.det.2024.02.003_bib12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jaad.2019.05.056","article-title":"Management of pediatric plaque psoriasis using biologics","volume":"82","author":"Lansang","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.02.003_bib13","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00431-011-1587-2","article-title":"Health-related quality of life of pediatric patients with moderate to severe plaque psoriasis: comparisons to four common chronic diseases","volume":"171","author":"Varni","year":"2012","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.det.2024.02.003_bib14","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2147\/PRBM.S117583","article-title":"Bidirectional relationships between psychological health and dermatological conditions in children","volume":"11","author":"Mitchell","year":"2018","journal-title":"Psychol Res Behav Manag"},{"issue":"6","key":"10.1016\/j.det.2024.02.003_bib15","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1001\/jamadermatol.2014.3593","article-title":"Economic Burden of Psoriasis in the United States: A Systematic Review","volume":"151","author":"Brezinski","year":"2015","journal-title":"JAMA Dermatology"},{"issue":"4","key":"10.1016\/j.det.2024.02.003_bib16","first-page":"e12801","article-title":"Pediatric dermatology-Critical approach to the new treatments","volume":"32","author":"Liang","year":"2019","journal-title":"Dermatol Ther"},{"issue":"3","key":"10.1016\/j.det.2024.02.003_bib17","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/09546634.2017.1364692","article-title":"Effectiveness of etanercept in children with plaque psoriasis in real practice: a one-year multicenter retrospective study","volume":"29","author":"Di Lernia","year":"2018","journal-title":"J\u00a0Dermatolog Treat"},{"issue":"2","key":"10.1016\/j.det.2024.02.003_bib18","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.det.2012.12.005","article-title":"Systemic treatments for severe pediatric psoriasis: a practical approach","volume":"31","author":"Marqueling","year":"2013","journal-title":"Dermatol Clin"},{"issue":"8","key":"10.1016\/j.det.2024.02.003_bib19","first-page":"e9812","article-title":"FDA Approved Biologics: Can Etanercept and Ustekinumab be Considered a First-Line Systemic Therapy for Pediatric\/Adolescents in Moderate to Severe Psoriasis? A Systematic Review","volume":"12","author":"Aslam","year":"2020","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.det.2024.02.003_bib20","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1001\/jamadermatol.2019.3717","article-title":"Association Between Quality of Life and Improvement in Psoriasis Severity and Extent in Pediatric Patients","volume":"156","author":"Bruins","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"11","key":"10.1016\/j.det.2024.02.003_bib21","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1001\/jamadermatol.2017.3029","article-title":"Safety of Systemic Agents for the Treatment of Pediatric Psoriasis","volume":"153","author":"Bronckers","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.02.003_bib22","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1615\/CritRevEukarGeneExpr.v20.i2.10","article-title":"Tumor Necrosis Factor-\u03b1 Signaling in Macrophages","volume":"20","author":"Parameswaran","year":"2010","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"10.1016\/j.det.2024.02.003_bib23","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/art.23427","article-title":"Pediatric Rheumatology Collaborative Study Group. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis","volume":"58","author":"Lovell","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.det.2024.02.003_bib24","first-page":"688","article-title":"Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis","volume":"26","author":"Nielsen","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.det.2024.02.003_bib25","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/ajg.2009.59","article-title":"Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn\u2019s disease: results from the CHARM trial [published online ahead of print April 7, 2009]","volume":"104","author":"Colombel","year":"2009","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.det.2024.02.003_bib26","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.0736-8046.2004.21121.x","article-title":"Successful treatment of pediatric psoriasis with infliximab","volume":"21","author":"Menter","year":"2004","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.02.003_bib27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5070\/D33XF9F397","article-title":"Successful use of infliximab following a failed course of etanercept in a pediatric patient","volume":"11","author":"Farnsworth","year":"2005","journal-title":"Dermatol Online J"},{"issue":"1","key":"10.1016\/j.det.2024.02.003_bib28","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1111\/pde.12457","article-title":"Childhood generalized pustular psoriasis: longtime remission with combined infliximab and methotrexate treatment","volume":"32","author":"Skrabl-Baumgartner","year":"2015","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.det.2024.02.003_bib29","series-title":"Enbrel (etanercept) [prescribing information]","year":"2023"},{"key":"10.1016\/j.det.2024.02.003_bib30","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa066886","article-title":"Etanercept treatment for children and adolescents with plaque psoriasis","volume":"358","author":"Paller","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.det.2024.02.003_bib31","first-page":"323","article-title":"Efficacy and safety of etanercept in children and adolescents aged\u00a0> or\u00a0= 8 years with severe plaque psoriasis","volume":"20","author":"Landells","year":"2010","journal-title":"Eur J Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.02.003_bib32","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/pde.12782","article-title":"Treatment of Moderate to Severe Pediatric Psoriasis: A Retrospective Case Series","volume":"33","author":"Klufas","year":"2016","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.02.003_bib33","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jaad.2015.09.056","article-title":"Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis","volume":"74","author":"Paller","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.det.2024.02.003_bib34","first-page":"928","article-title":"Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study","volume":"9","author":"Leonardi","year":"2010","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.02.003_bib35","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jaad.2009.10.046","article-title":"Intermittent etanercept therapy in pediatric patients with psoriasis","volume":"63","author":"Siegfried","year":"2010","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2024.02.003_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/AHMT.S8163","article-title":"Safety of TNF inhibitors in adolescents and children","volume":"2","author":"McCluggage","year":"2010","journal-title":"Adolesc Health Med Therapeut"},{"issue":"1","key":"10.1016\/j.det.2024.02.003_bib37","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jaad.2010.02.060","article-title":"Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial","volume":"64","author":"Langley","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.02.003_bib38","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1080\/09546634.2021.1914306","article-title":"Biologics recommendations for patients with psoriasis: a critical appraisal of clinical practice guidelines for psoriasis","volume":"33","author":"Xie","year":"2022","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.det.2024.02.003_bib39","series-title":"Humira (INN-adalimumab) [summary of product characteristics]","year":"2022"},{"key":"10.1016\/j.det.2024.02.003_bib40","series-title":"Adalimumab (adalimumab-adaz) [prescribing information]","year":"2023"},{"issue":"10089","key":"10.1016\/j.det.2024.02.003_bib41","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(17)31189-3","article-title":"Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial","volume":"390","author":"Papp","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.det.2024.02.003_bib42","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/bjd.18029","article-title":"Sustained long-term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double-blind, phase III study","volume":"181","author":"Tha\u00e7i","year":"2019","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.02.003_bib43","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1080\/09546634.2022.2089327","article-title":"Efficacy of adalimumab in pediatric generalized pustular psoriasis: case series and literature review","volume":"33","author":"Du","year":"2022","journal-title":"J\u00a0Dermatolog Treat"},{"issue":"3","key":"10.1016\/j.det.2024.02.003_bib44","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"10.1016\/j.det.2024.02.003_bib45","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/09546634.2020.1737638","article-title":"Off-label dermatologic uses of IL-17 inhibitors","volume":"33","author":"Wu","year":"2022","journal-title":"J\u00a0Dermatol Treat"},{"issue":"6","key":"10.1016\/j.det.2024.02.003_bib46","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s40272-021-00476-w","article-title":"Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis","volume":"23","author":"Blair","year":"2021","journal-title":"Pediatr Drugs"},{"issue":"8","key":"10.1016\/j.det.2024.02.003_bib47","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1080\/14712598.2021.1931679","article-title":"Ixekizumab for the treatment of pediatric patients with moderate to severe plaque psoriasis","volume":"21","author":"Cather","year":"2021","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"10.1016\/j.det.2024.02.003_bib48","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.det.2021.12.003","article-title":"Clinical Decisions in Pediatric Psoriasis: A Practical Approach to Systemic Therapy","volume":"40","author":"Ornelas","year":"2022","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.det.2024.02.003_bib49","series-title":"Cosentyx (secukinumab) [summary of the product characteristics]","year":"2020"},{"key":"10.1016\/j.det.2024.02.003_bib50","series-title":"Cosentyx (secukinumab) [prescribing information]","year":"2023"},{"key":"10.1016\/j.det.2024.02.003_bib51","doi-asserted-by":"crossref","first-page":"944208","DOI":"10.3389\/fmed.2022.944208","article-title":"Understanding efficacy-safety balance of biologics in moderate-to-severe pediatric psoriasis","volume":"9","author":"Golhen","year":"2022","journal-title":"Front Med"},{"issue":"4","key":"10.1016\/j.det.2024.02.003_bib52","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/jdv.17002","article-title":"Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial","volume":"35","author":"Bodemer","year":"2021","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.det.2024.02.003_bib53","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jaad.2021.08.066","article-title":"A\u00a0phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results","volume":"86","author":"Magnolo","year":"2022","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2024.02.003_bib54","doi-asserted-by":"crossref","DOI":"10.1007\/s40257-023-00782-8","article-title":"Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical Trials","author":"Sticherling","year":"2023","journal-title":"Am J Clin Dermatol"},{"issue":"7","key":"10.1016\/j.det.2024.02.003_bib55","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1080\/14740338.2022.2073349","article-title":"Safety evaluation of secukinumab in pediatric patients with plaque psoriasis","volume":"21","author":"Bardowska","year":"2022","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"10.1016\/j.det.2024.02.003_bib56","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jaad.2016.03.024","article-title":"Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis","volume":"75","author":"van de Kerkhof","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2024.02.003_bib57","series-title":"Taltz (ixekixzumab) [prescribing information]","year":"2022"},{"issue":"2","key":"10.1016\/j.det.2024.02.003_bib58","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/bjd.19147","article-title":"Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS)","volume":"183","author":"Paller","year":"2020","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.det.2024.02.003_bib59","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1084\/jem.20060244","article-title":"IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis","volume":"203","author":"Chan","year":"2006","journal-title":"J\u00a0Exp Med"},{"issue":"24","key":"10.1016\/j.det.2024.02.003_bib60","doi-asserted-by":"crossref","first-page":"14002","DOI":"10.1073\/pnas.93.24.14002","article-title":"A\u00a0functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits","volume":"93","author":"Presky","year":"1996","journal-title":"Proc Nat Acad Sci"},{"issue":"1","key":"10.1016\/j.det.2024.02.003_bib61","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1084\/jem.20030451","article-title":"Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris","volume":"199","author":"Lee","year":"2004","journal-title":"J\u00a0Exp Med"},{"issue":"2","key":"10.1016\/j.det.2024.02.003_bib62","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40257-020-00578-0","article-title":"Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review","volume":"22","author":"Yang","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.det.2024.02.003_bib63","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jaad.2015.07.002","article-title":"Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study","volume":"73","author":"Landells","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2024.02.003_bib64","series-title":"Stelara (ustekinumab) [prescribing information]","year":"2022"},{"issue":"4","key":"10.1016\/j.det.2024.02.003_bib65","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/bjd.19018","article-title":"Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (\u2265 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open-label CADMUS Jr study","volume":"183","author":"Philipp","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2024.02.003_bib66","article-title":"Fear of Injections and Needle Phobia Among Children and Adolescents: An Overview of Psychological, Behavioral, and Contextual Factors","volume":"4","author":"Orenius","year":"2018","journal-title":"SAGE Open Nurs"},{"issue":"2","key":"10.1016\/j.det.2024.02.003_bib67","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1001\/jamadermatol.2013.1078","article-title":"Association of pediatric psoriasis severity with excess and central adiposity: an international cross-sectional study","volume":"149","author":"Paller","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.det.2024.02.003_bib68","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.clindermatol.2014.12.006","article-title":"Obesity and the metabolic syndrome in pediatric psoriasis","volume":"33","author":"Gutmark-Little","year":"2015","journal-title":"Clin Dermatol"},{"issue":"11","key":"10.1016\/j.det.2024.02.003_bib69","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1001\/archdermatol.2012.2502","article-title":"Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis","volume":"148","author":"Wu","year":"2012","journal-title":"Arch Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.02.003_bib70","first-page":"249","article-title":"Vaccination Recommendations for Psoriasis and Atopic Dermatitis Patients on Biologic Therapy: A Practical Guide","volume":"95","author":"Fan","year":"2022","journal-title":"Yale J Biol Med"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863524000159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863524000159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T21:38:59Z","timestamp":1716500339000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863524000159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0733863524000159"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2024.02.003","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolving Landscape of Biologic Therapy for Pediatric Psoriasis","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2024.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}